Discover the winners of the 2015 edition of the Innovation Prize by Universal Biotech
The excellence of innovation in life sciences
For this 6th edition, Universal Medica Group have gathered 450 international actors of the life sciences during the Innovation Days. During these two days of partnering and conferences, Biotech, Medtech and e-health private and academic researchers have pitched their projects to industrials and pharmaceutical executives.
The Innovation Prize, an initiative by Universal Biotech
6 finalists were nominated and assisted to the ceremony. They were selected from 136 eligible projects issued from the 289 applications representing 34 countries. Selection criteria were based on the scientific quality of the innovation, IP, industrial feasibility and HR quality.
The Innovation Prize differentiates itself by the pertinence of the projects highlighted by the jury : 59% of the laureates raised funds or managed industrial partnerships with pharma and investors after their nomination. Jury composition is available at the end of the article. (2).
And the Innovation Prize ceremony awarded:
New technologies at the interface of vision:
Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision’s VRS are associated with a surgical intervention as well as a rehabilitation period.
A first-in-class, catheter-deployed circulatory assistance device for treating heart failure
The Procyrion (Houston, TX) device consists of a small, continuous flow pump mounted within a self-expanding anchoring system. The device is advanced through a catheter in the femoral artery to the descending thoracic aorta. The self-expanding anchors deploy to fix the pump to the aortic wall. Following deployment, the catheter is fully removed, leaving only the anchored pump and a small diameter, flexible electrical power wire which may be tunneled to a desired transdermal exit site or to a Transcutaneous Energy Transfer (TET) system for subcutaneous implantation without an indwelling power lead. Compared to traditional LVADs, Procyrion replaces a major surgery and a lengthy hospital stay with a minimally invasive outpatient procedure.
Let’s keep in touch for the 2016 edition !
Save the date : 3rd and 4th october 2016 in Paris !
(2) Composition of the 2015 Innovation Prize Jury
• Rodica ADABII, GSK Pharma
• Zeina ANTOUN, GlaxoSmithKline
• Jean DEREGNAUCOURT, Institut Pasteur
• Olivier GUERY, Servier
• Olivier GUTH, Mayoly-Spindler
• Antony LEBEAU, Agence Nationale de Recherche
• Andrea LYMBERIS, Commission Européenne
• Rafi MARDACHTI, Universal Medica Group
• Fréderic SCAEROU, Ipsen
• Ola WINQVIST, Karolinska Institute